Skip to Content

How is Kyprolis (carfilzomib) administered?

Medically reviewed by N. France, BPharm. Last updated on July 14, 2020.

How is Kyprolis (carfilzomib) given?

Official Answer

by Drugs.com

Kyprolis (carfilzomib) for injection is given as an intravenous (IV) infusion, which involves delivering the medication directly into a vein via a needle. A Kyprolis infusion is usually administered in a clinic, hospital or doctor’s office.

Kyprolis is used to treat relapsed or refractory multiple myeloma and may be given on its own or in combination with dexamethasone or with lenalidomide plus dexamethasone.

How long does it take to receive a Kyprolis infusion?

The amount of time it takes to infuse Kyprolis depends on the dose regimen required and varies from 10 to 30 minutes.

  • When Kyprolis is administered on its own it is infused over either 10 minutes or 30 minutes.
  • When Kyprolis is administered with dexamethasone it is infused over a period of 30 minutes.
  • When Kyprolis is administered with lenalidomide plus dexamethasone it is infused over a period of 10 minutes.

How many times a week will I receive a Kyprolis infusion?

The number of infusions you receive in a week depends on the treatment combination being used. Kyprolis may be given on two consecutive days or once a week.

  • When Kyprolis is administered on its own it is infused on two consecutive days each week.
  • When Kyprolis is administered with dexamethasone it is given on either two consecutive days each week or once a week.
  • When Kyprolis is administered with lenalidomide plus dexamethasone it is infused on two consecutive days each week.

How long is a treatment cycle for Kyprolis?

A standard Kyprolis treatment cycle involves receiving infusions for three consecutive weeks, followed by one week off of treatment.

What precautions need to be taken when Kyprolis is being administered?

Standard administration precautions include:

  • Ensuring the patient is adequately hydrated, especially before the first dose of Kyprolis is given and also in patient’s at high risk of tumor lysis syndrome (TLS) or kidney toxicity.
  • Monitoring of serum potassium levels, which should be done regularly during treatment.
  • Pre-treatment with dexamethasone to reduce the incidence of and severity of infusion-related adverse reactions.
  • Administering medication to prevent blood clots in patients receiving Kyprolis and dexamethasone or with lenalidomide plus dexamethasone.
  • Administering antiviral medications to prevent herpes reactivation in those patients at risk.
  • Administering Kyprolis after hemodialysis in those patients who receive it.
References

Related Medical Questions

Drug Information

Related Support Groups